Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin dosing: 2017 Update

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.

Related collections

Author and article information

Journal

Journal ID (nlm-journal-id): 0372741

Journal ID (pubmed-jr-id): 3058

Journal ID (nlm-ta): Clin Pharmacol Ther

Journal ID (iso-abbrev): Clin. Pharmacol. Ther.

Title: Clinical pharmacology and therapeutics

ISSN (Print): 0009-9236

ISSN (Electronic): 1532-6535

Publication date Nihms-submitted: 16 February 2017

Publication date (Electronic): 04 April 2017

Publication date (Print): September 2017

Publication date PMC-release: 01 September 2018

Volume: 102

Issue: 3

Pages: 397-404

Affiliations

[1 ]Department of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA

[2 ]Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN

[3 ]Department of Biomedical Data Science, Stanford University, Stanford, California, USA

[4 ]Division of Clinical Pharmacology Vanderbilt Medical School, Nashville, TN, USA

[5 ]Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

[6 ]Laboratory for International Alliance on Genomic Research, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; National Center for Genome Medicine; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Genomic Medicine Institute Geisinger Health system, Danville, PA

[7 ]Department of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri

[8 ]Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

[9 ]Department of Medicine and Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

[10 ]Department of Medicine, University of Chicago, Chicago, IL, USA

[11 ]Intermountain Heart Institute, Intermountain Medical Center, and Department of Internal Medicine (Cardiology), University of Utah School of Medicine, Salt Lake City, Utah

[12 ]Department of Molecular and Clinical Pharmacology; The Wolfson Centre for Personalised Medicine; Institute of Translational Medicine, University of Liverpool, Liverpool

[13 ]Department of Neurology and Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA

[14 ]Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden

Author notes

Corresponding author: Julie A. Johnson, PharmD.; Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Box 100484, Gainesville, FL 32610-0486; phone: 352-273-6309; fax: 352-273-6306; Johnson@ 123456cop.ufl.edu

Article

Accession ID: PMC5546947 Pmcid ID: PMC5546947 Pmc-uid ID: 5546947 Manuscript ID: nihpa851971

DOI: 10.1002/cpt.668

PMC ID: 5546947

PubMed ID: 28198005

SO-VID: c75d1ab7-d4c8-43f1-bfdd-d849eadf6171

History

Comments

Comment on this article

scite_

Cited by 183

See all cited by

- Version 1